Discovery and Developmental Therapeutics (DDT) Program is the primary driver of discovery and evaluation of novel therapeutic options for patients with cancer at the Winship Cancer Institute. The DDT Program has developed and recruited expertise focused on four specific interconnected goals: 1) to identify small molecule cancer therapeutics;2) to translate discoveries in cancer immunology into enhanced therapies;3) to develop innovative in vivo imaging technologies;and 4) to accelerate targeted therapeutics into clinical trials. DDT Program members pursue these goals In the lab and in clinic, providing numerous opportunities for dynamic collaboration both intra- and inter-programmatically. DDT members published 505 cancer-related publications in the current project period and demonstrated that they are active as well as interactive. Specifically, intra-programmatic publications account for 23% and inter-programmatic publications account for 25% of their total cancer-relevant publications. The DDT Program has met significant milestones in pursuing its goals by capitalizing on its members'strengths and the opportunities available to them. DDT's 52 core members represent 14 departments across Emory University, including the School of Medicine, the School of Public Health and Emory College. DDT members currently have $34,792,000 in research grant funding (annual direct costs), of which $24,711,747 is peer-reviewed and $12,405,796 is NCI funded. Scientific advances are made possible by access to outstanding shared resources, the opportunity to compete for various funding sources, and the provision of matching funds for large research grants. These opportunities, combined with capable leadership, will continue to enable the DDT Program to translate technologic advances into therapeutic options for patients with cancer.

Public Health Relevance

The Discovery and Developmental Therapeutics Program of the Winship Cancer Institute is the primary driver of discovery and evaluation of novel therapeutic options for patients with cancer seen at Winship.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-05
Application #
8520237
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$22,395
Indirect Cost
$8,039
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Danish, Hasan; Ferris, Matthew J; Balagamwala, Ehsan et al. (2018) Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res 28:120-125
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Liu, Fakeng; Liu, Yuan; Liu, Xiuju et al. (2018) Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer 123:36-43
Kennedy, E M; Powell, D R; Li, Z et al. (2018) Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer. Sci Rep 8:6709
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697

Showing the most recent 10 out of 331 publications